PE20070076A1 - Aminopirimidinas como moduladores de quinasas - Google Patents
Aminopirimidinas como moduladores de quinasasInfo
- Publication number
- PE20070076A1 PE20070076A1 PE2006000625A PE2006000625A PE20070076A1 PE 20070076 A1 PE20070076 A1 PE 20070076A1 PE 2006000625 A PE2006000625 A PE 2006000625A PE 2006000625 A PE2006000625 A PE 2006000625A PE 20070076 A1 PE20070076 A1 PE 20070076A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- alkyl
- pyrimidin
- piperidin
- ester
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 150000005005 aminopyrimidines Chemical class 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- FSMDIXFTJVXPHR-UHFFFAOYSA-N (4-propan-2-yloxyphenyl)carbamic acid Chemical compound CC(C)OC1=CC=C(NC(O)=O)C=C1 FSMDIXFTJVXPHR-UHFFFAOYSA-N 0.000 abstract 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101150056950 Ntrk2 gene Proteins 0.000 abstract 1
- -1 PHENOXY, PHENYL Chemical class 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
REFERIDA A UN COMPUESTO DE FORMULA (I), DONDE q ES 0, 1 O 2; p ES 0 O 1; Q ES NH, N(ALQUILO), O, O UN ENLACE DIRECTO; Z ES NH, N(ALQUILO), CH2; B ES FENILO, HETEROARILO, O UN HETEROARILO BENZO-FUSIONADO DE UNO A NUEVE MIEMBROS; R1 ES -(CH2)n-Ra; n ES 1, 2, 3 O 4; Ra ES H, ALCOXI, FENOXI, FENILO, ENTRE OTROS; R3 ES H, ALQUILO, ALCOXI, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1- 6-AMINO-5-(METOXIIMINO-METIL)-PIRIMIDIN-4-IL -PIPERIDIN-4-IL ESTER DEL ACIDO (4-ISOPROPOXI-FENIL)-CARBAMICO, 1-{6-AMINO-5-[(2-MORFOLIN-4-IL-ETOXIIMINO)-METIL]-PIRIMIDIN-4-IL}-PIPERIDIN-4-IL ESTER DEL ACIDO (4-ISOPROPOXI-FENIL)-CARBAMICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON MODULADORES DE PROTEINA TIROSINA QUINASAS, PARTICULARMENTE, INHIBEN LA ACTIVIDAD DE LA QUINASA FLT3 Y/O C-KIT Y/O TrKB Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS PROLIFERATIVOS CELULARES TALES COMO CANCER, ENTRE OTROS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68971705P | 2005-06-10 | 2005-06-10 | |
| US75108405P | 2005-12-16 | 2005-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070076A1 true PE20070076A1 (es) | 2007-02-09 |
Family
ID=36929309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000625A PE20070076A1 (es) | 2005-06-10 | 2006-06-07 | Aminopirimidinas como moduladores de quinasas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20060281764A1 (es) |
| EP (1) | EP1896029A1 (es) |
| JP (1) | JP2008543760A (es) |
| KR (1) | KR20080028911A (es) |
| AR (1) | AR053895A1 (es) |
| AU (1) | AU2006258054A1 (es) |
| BR (1) | BRPI0611963A2 (es) |
| CA (1) | CA2611470A1 (es) |
| EA (1) | EA200800015A1 (es) |
| EC (1) | ECSP077991A (es) |
| GT (1) | GT200600248A (es) |
| IL (1) | IL187693A0 (es) |
| NI (1) | NI200700316A (es) |
| NO (1) | NO20080163L (es) |
| PE (1) | PE20070076A1 (es) |
| TW (1) | TW200718693A (es) |
| WO (1) | WO2006135644A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080043840A (ko) * | 2005-09-13 | 2008-05-19 | 팔라우 파르마 에스에이 | 히스타민 ｈ4 수용체 활성의 조정자로서 2-아미노피리미딘유도체 |
| CN101511359B (zh) | 2006-09-08 | 2012-09-05 | 霍夫曼-拉罗奇有限公司 | 苯并三唑激酶调节剂 |
| EP2066642A1 (en) * | 2006-09-25 | 2009-06-10 | Arete Therapeutics, INC. | Soluble epoxide hydrolase inhibitors |
| US20080234332A1 (en) * | 2007-03-20 | 2008-09-25 | Xiong Cai | Raf kinase inhibitors containing a zinc binding moiety |
| JP2012508367A (ja) * | 2008-11-06 | 2012-04-05 | アムビト ビオスシエンセス コルポラチオン | リン酸化型ｆｍｓ関連チロシンキナーゼ３バイオマーカーアッセイ |
| CN102272120B (zh) * | 2008-11-07 | 2013-12-25 | H.隆德贝克有限公司 | 生物活性酰胺 |
| JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| US8785440B2 (en) | 2009-09-04 | 2014-07-22 | Biogen Idec Ma, Inc. | Bruton's tyrosine kinase inhibitors |
| AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| KR20190035769A (ko) | 2016-07-21 | 2019-04-03 | 바이오젠 엠에이 인코포레이티드 | 브루톤 타이로신 카이나제 저해제의 석신에이트 형태 및 조성물 |
| ES2850349T3 (es) * | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| EA201992083A1 (ru) * | 2017-03-16 | 2020-03-18 | Кринетикс Фармасьютикалс, Инк. | Модуляторы соматостатина и их применения |
| EP3752498B1 (en) | 2018-02-12 | 2023-06-28 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| DK3853218T3 (da) | 2018-09-18 | 2025-04-22 | Crinetics Pharmaceuticals Inc | Somatostatinmodulatorer og anvendelser deraf |
| TWI841768B (zh) | 2019-08-14 | 2024-05-11 | 美商克林提克斯醫藥股份有限公司 | 非肽生長抑制素(somatostatin)5型受體激動劑及其用途 |
| CN117043149A (zh) | 2021-02-17 | 2023-11-10 | 克林提克斯医药股份有限公司 | 促生长素抑制素调节剂的结晶形式 |
| WO2024129614A1 (en) | 2022-12-13 | 2024-06-20 | Crinetics Pharmaceuticals, Inc. | Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof |
| EP4553080A1 (en) | 2023-11-07 | 2025-05-14 | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. | Nucleoside derivatives as antiviral agents against coronaviruses |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1206265B1 (en) * | 1999-06-30 | 2003-11-12 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| WO2003026666A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors |
-
2006
- 2006-06-06 US US11/422,362 patent/US20060281764A1/en not_active Abandoned
- 2006-06-07 BR BRPI0611963-8A patent/BRPI0611963A2/pt not_active Application Discontinuation
- 2006-06-07 JP JP2008515885A patent/JP2008543760A/ja not_active Withdrawn
- 2006-06-07 CA CA002611470A patent/CA2611470A1/en not_active Abandoned
- 2006-06-07 EA EA200800015A patent/EA200800015A1/ru unknown
- 2006-06-07 NI NI200700316A patent/NI200700316A/es unknown
- 2006-06-07 AU AU2006258054A patent/AU2006258054A1/en not_active Abandoned
- 2006-06-07 EP EP06772456A patent/EP1896029A1/en not_active Withdrawn
- 2006-06-07 KR KR1020087000399A patent/KR20080028911A/ko not_active Withdrawn
- 2006-06-07 PE PE2006000625A patent/PE20070076A1/es not_active Application Discontinuation
- 2006-06-07 WO PCT/US2006/022165 patent/WO2006135644A1/en not_active Ceased
- 2006-06-08 GT GT200600248A patent/GT200600248A/es unknown
- 2006-06-09 AR ARP060102426A patent/AR053895A1/es not_active Application Discontinuation
- 2006-06-09 TW TW095120473A patent/TW200718693A/zh unknown
-
2007
- 2007-11-27 IL IL187693A patent/IL187693A0/en unknown
- 2007-12-10 EC EC2007007991A patent/ECSP077991A/es unknown
-
2008
- 2008-01-09 NO NO20080163A patent/NO20080163L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NI200700316A (es) | 2009-03-03 |
| NO20080163L (no) | 2008-03-07 |
| IL187693A0 (en) | 2008-08-07 |
| EP1896029A1 (en) | 2008-03-12 |
| GT200600248A (es) | 2007-03-14 |
| CA2611470A1 (en) | 2006-12-21 |
| WO2006135644A1 (en) | 2006-12-21 |
| KR20080028911A (ko) | 2008-04-02 |
| AR053895A1 (es) | 2007-05-23 |
| ECSP077991A (es) | 2008-01-23 |
| BRPI0611963A2 (pt) | 2010-10-13 |
| TW200718693A (en) | 2007-05-16 |
| EA200800015A1 (ru) | 2008-06-30 |
| AU2006258054A1 (en) | 2006-12-21 |
| US20060281764A1 (en) | 2006-12-14 |
| JP2008543760A (ja) | 2008-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070076A1 (es) | Aminopirimidinas como moduladores de quinasas | |
| PE20060501A1 (es) | Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa | |
| PE20091955A1 (es) | Derivados de quinoxalin- y quinolin-carboxamida | |
| PE20081256A1 (es) | Triazalopiridacina como modulador de la actividad proteina cinasa | |
| PE20070113A1 (es) | Derivados de quinolina y quinazolina como inhibidores de tirosinquinasas flt3 y trkb | |
| PE20090982A1 (es) | Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp) | |
| PE20120546A1 (es) | Inhibidores del virus de la hepatitis c | |
| PE20070790A1 (es) | Derivados de 2-aminopirimidina como moduladores de la actividad del receptor de histamina h-4 | |
| PE20120834A1 (es) | Derivados de furopirimidindiona como moduladores de trpa1 | |
| PE20110419A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk | |
| PE20060479A1 (es) | Compuestos heteroaril-aril-ureas como inhibidores de la quinasa | |
| PE20141702A1 (es) | Compuestos de carbamato y preparacion y uso de los mismos | |
| PE20090649A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
| PE20060374A1 (es) | Inhibidores de cinasa heterociclicos fusionados | |
| PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
| PE20142185A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| PE20141855A1 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| PE20110545A1 (es) | Compuestos de triazolopiridina como inhibidores de jak | |
| PE20120533A1 (es) | Inhibidores del virus de la hepatitis c | |
| PE20040647A1 (es) | Inhibidores de cinasas de tirosina | |
| EA200700192A1 (ru) | Производные фталазина в качестве ингибиторов parp | |
| PE20070070A1 (es) | Derivados de tienopiridina y tienopirimidina como agentes moduladores de tirosinquinasa | |
| NO20080161L (no) | Aminopyrimidiner som kinasemodulatorer | |
| PE20110560A1 (es) | NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET | |
| PE20091243A1 (es) | Compuesto heterociclico fusionado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |